Correspondence on 'Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised controlled trial'

Ann Rheum Dis. 2023 Jun;82(6):e148. doi: 10.1136/annrheumdis-2021-220198. Epub 2021 Mar 23.

Authors

Liseth de Wolff¹, Suzanne Arends¹, Gwenny M Verstappen¹, Arjan Vissink², Frans G M Kroese¹, Hendrika Bootsma³

Affiliations

¹ Rheumatology and Clinical Immunology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
² Oral and Maxillofacial Surgery, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
³ Rheumatology and Clinical Immunology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands [email protected].

PMID: 33757967
DOI: 10.1136/annrheumdis-2021-220198

No abstract available

Keywords: Sjogren's syndrome; health care; outcome assessment; therapeutics.

Publication types

Letter
Comment

MeSH terms

Double-Blind Method
Humans
Multicenter Studies as Topic
Randomized Controlled Trials as Topic
Receptors, Interleukin-6* / antagonists & inhibitors
Sjogren's Syndrome* / drug therapy

Substances

Receptors, Interleukin-6